SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David Bogdanoff who wrote (987)12/1/1997 7:49:00 PM
From: D.Right  Read Replies (1) of 2173
 
Dear David:

Yuor first answer is very unlikely because they had the data of increased and decreased use of insulin (I believe by "they simply didn't know this possibility" you meant they did not collect any data in that regard at all). Your second answer must be it. For the trial medicine, pramlintide here, it has to be handled by the doctors and nurses, but I would imagine the patients would still give themself insulin and then just tell the nurses how much they used. That may very well lead to what you refered to as "data collected was not of high enough quality".

Thanks

D.Right
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News